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In high-throughput genomics, large-scale designed experiments
are becoming common, and analysis approaches based on highly mul-
tivariate regression and anova concepts are key tools. Shrinkage mod-
els of one form or another can provide comprehensive approaches to
the problems of simultaneous inference that involve implicit multiple
comparisons over the many, many parameters representing effects of
design factors and covariates. We use such approaches here in a study
of cardiovascular genomics. The primary experimental context con-
cerns a carefully designed, and rich, gene expression study focused on
gene-environment interactions, with the goals of identifying genes im-
plicated in connection with disease states and known risk factors, and
in generating expression signatures as proxies for such risk factors.
A coupled exploratory analysis investigates cross-species extrapola-
tion of gene expression signatures—how these mouse-model signa-
tures translate to humans. The latter involves exploration of sparse
latent factor analysis of human observational data and of how it re-
lates to projected risk signatures derived in the animal models. The
study also highlights a range of applied statistical and genomic data
analysis issues, including model specification, computational ques-
tions and model-based correction of experimental artifacts in DNA
microarray data.
1. Introduction. As part of a program of research in the genomics of
atherosclerosis, we have developed studies that involve evaluation of DNA
microarray gene expression data, and other forms of molecular and physi-
ological data, in both experimental and observational contexts. This paper
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represents a case study of experimental data from animal models coupled
with human observational data. The study highlights questions of gene iden-
tification related to disease risk factors, assessment of expression-based sig-
natures of physiological and disease states based on animal model designed
experiments, and evaluation of such signatures in data arising from human
observational studies. The analysis is developed in a class of multivariate
regression and factor models utilizing sparsity priors; the application is il-
lustrative of the utility of this approach in high-throughput genomic studies.
The paper describes aspects of the modeling framework, including concep-
tual, practical and computational questions. These are developed throughout
the applied studies in two model contexts: multivariate regression and anova
applied to the designed experiment on mice models, and multivariate factor
analysis of human data. We also highlight the biological relevance and spe-
cific methods of extrapolation of expression signatures derived in controlled
experimental conditions to observational settings.
2. Cardiovascular genomics and atherosclerosis. Atherosclerosis—the de-
velopment of hardened, flow-limiting plaque within arterial vessels—is a
chronic human condition with a complex developmental process that is
driven by, and responsive to, many lifestyle and environmental factors over-
laying genetic determinants. The gradual build-up of arterial plaque based
on blood-borne fats, cholesterols, collagens, cell proliferation, calcium and
other substances narrows the inside of the artery and can restrict blood flow.
Arterial plaques may also rupture to cause clots with severe and often deadly
results. The process of atherogenesis plays roles in coronary artery and cere-
brovascular diseases, and is thus central to the leading causes of chronic
illness and death in the Western world. Inherent and genetic risk factors for
development and aggressiveness of the disease include gender, age and family
history of premature cardiovascular disease. Atherosclerosis starts in early
ages and progresses throughout our lifetime, to greater or lesser degrees as
a function of these and other genetic factors as well as lifestyle activities.
Among controllable environmental risk factors, diet is key. Dietary fats are
fundamental to the drivers of serum cholesterol distribution and triglyceride
levels that are key contributors to disease risk. Improved understanding of
the progression of atherosclerosis, the roles of known risk factors and their
interactions with genetic factors, are needed to improve risk assessment and
therapy. Here we are concerned with questions of profiling disease states and
progression using DNA microarray data as part of this overall enterprise.
Some of our prior work has investigated expression data derived from
the inner walls of human aorta. Using aortic tissues from heart donors, this
led to the identification of signatures predictive of atherosclerotic disease
burden. The extent of disease development within the inner walls of the
aorta can be assessed visually for signs of lesions linked to advanced plaque
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development, and also staining methods that are expected to reflect early
atherosclerotic plaque development in terms of fatty streaks [11, 12]. Gene
signatures based on clustering and binary regression tree model analysis to
predict “minimal” versus “advanced” disease using simple binary summaries
of staining and lesion were developed in [51]. A challenge in this area is that
of more precise measures of disease extent; the traditional SudanIV staining
methods [11, 12] and the evaluation of relative extent of lesion development
are current gold standards but nevertheless represent very noisy and im-
precise clinical phenotypes. More advanced clinical diagnostic methods are
unable to predict clinical outcomes for a given patient, and these traditional
physiological determinations remain the state-of-the-art clinical phenotypes
related to disease burden. The existence of advanced raised lesions within
the aorta, compared to no such evidence, was central to [51] and we refer to
this clinical binary outcome in our exploratory analysis here.
The starting point of the current paper is new experimental data that
explores genetic and environmental risk factors in atherosclerosis in animal
models. Before genomic data can be widely used to identify patient risk in
human populations, we must first understand which genes and their vari-
ants actually reflect and contribute to disease. More specifically, we must
understand which genetic variants interact with particular environmental
risk factors, and need increased efforts to define controlled studies evaluating
responses to environmental exposures. Such studies will naturally continue
to heavily require murine (and other) disease models. Some aspects of a new
and rich data set generated from such a study on mice have already illumi-
nated the disease process [31]. Some direct comparisons of gene expression
data from subsets of mice in the experiment to be described further below
identified gene subsets and expression signatures predictive of disease state
and linked the results to potential functional associations with the develop-
ment of arterial repair mechanisms. The current paper develops a broader
and detailed study with an expanded experimental mice data set, aiming to
explore the cross-connections between environmental risk factors that may
modify disease susceptibility by affecting gene expression.
3. Profiling atherosclerotic disease risk: A gene-environment interaction
study. Our experimental study involves a cross-classified, multi-factorial
design to generate gene expression from arterial tissues in the main aortas
of mice. The study investigates three key environmental risk factors—Age,
Gender and Dietary fat intake—coupled with a key genetic factor related to
the ApoE (Apolipoprotein E) gene pathway. ApoE has many known func-
tions linked to fat metabolism and dietary molecular transport [44]. The
ApoE protein forms a component of cholesterol complexes that play roles
in the transport of triglycerides and in cholesterol distribution among cells.
It is further involved in lipid metabolism and the binding of lipoproteins to
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Table 1
Design layout, (0/1) coding of factor levels, β·,· notation for effects, and actual sample
sizes (in parentheses) for the mouse model expression experiment (see also Table 1 of the
supplementary material)
Wild Type (0) ApoE-/- (1)
Chow diet (0) Western diet (1) Chow diet (0) Western diet (1)
6 week (0)
Female (0): βg,1 (5) +βg,5 (5) +βg,2 (6) +βg,8 (4)
Male (1): +βg,4 (5) +βg,11 (5) +βg,7 (8) +βg,14 (5)
12 week (1)
Female (0): βg,3 (5) +βg,10 (6) +βg,6 (3) +βg,13 (9)
Male (1): +βg,9 (5) +βg,15 (5) +βg,12 (3) +βg,16 (11)
the LDL receptors that feed into cellular uptake of lipoproteins for choles-
terol metabolism [36]. It is well known that ApoE deficiency is a major
genetic risk factor for atherosclerosis, causing high serum cholesterol and
triglyceride levels and leading to premature and advanced disease [34]. The
ApoE knockout (ApoE-/-) mouse model closely mimics human atherosclero-
sis both in the spontaneous appearance of lesions and in the distribution of
lesions within blood vessels. In contrast, wild type (WT) mice have intrinsic
resistance to atherosclerosis.
Our experimental design provides data on aortic gene expression linked
to aging, diet, gender, the ApoE deletion and the interactions of these fac-
tors. We aim to explore whether there are patterns of gene expression that
vary with dietary fat content, with gender, with aging and with the dele-
tion of the ApoE locus, and to define gene subsets underlying any such
patterns for further study, interpretation and annotation. Wild type and
ApoE-/-(C57BL/6J) mice from the Jackson laboratories were used, with
mice pups weaned at three weeks of age and fed either the regular chow
diet or the high-fat, Western diet and then grown to either 6 weeks or 12
weeks of age. Aortic tissue was removed at the 6 or 12 week end point (all
mouse work was approved by the Duke University IACUC under protocol
A288-02-09).
The design and numbers of mice are in Table 1. The design is a saturated
cross-classification of ApoE, Age, Gender and Diet, with several replicates in
each cell. This enables study of the impact on aortic gene expression of the
risk-related genotype (Wild Type versus ApoE-/-), Age (“young” = 6 week
old, versus “old” = 12 week old), gender (female versus male) and dietary
fat content (standard, low fat “chow” diet versus high-fat “Western” diet),
and all levels of interactions. Roughly half the mice are ApoE-/-mutants,
roughly half are older, roughly half are males and roughly half are fed the
high fat, Western diet. The balance and replication lead to a well-structured
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design for the evaluation of expression variation related to main effects and
potential interactions of genetic and environmental factors.
Disease development was studied by staining the aortic tissue to assess the
extent and nature of lesion development [31]. This confirmed intensification
of disease burden with age, diet and ApoE-/- and that disease is markedly
increased in the older, mutant mice on the high fat diet. We therefore refer
to these risk factors as defining disease related states of increasing severity
as a function of level of interaction. Each aorta generated mRNA extraction
for microarray analysis at the Duke University Microarray Core Facility.
This involved standard quality analysis (Agilent Bioanalyzer), then cDNA
synthesis and hybridization to the MG-U74Av2 oligonucleotide microarray
(Affymetrix). The resulting samples were processed using the RMA [26, 27]
delivering measures, on a log2 scale, of expression intensities for each of the
12488 gene probe sets on each mouse array.
4. Multivariate sparse anova model.
4.1. Basic model form. Write xg,i for the expression intensity of gene
g = 1 :p on sample (mouse) i= 1 :n. For each gene g, a linear anova model
is then defined by the n× k design matrix H of 0/1 entries corresponding
to the design and parameters in Table 1. With the k = 16 βg,· parameters
defining the k-vector of effects βg = (βg,1, . . . , βg,k)
′, we have
xg,i =
k∑
j=1
βg,jhj,i + εg,i = β
′
ghi + εg,i,
where the k-vector hi = (h1,i, . . . , hk,i)
′ is the ith row of H . Our analysis
assumes a normal residual distribution, εg,i ∼N(0, ψg) independently. This
represents the combination of unexplained biological variation in expres-
sion of gene g, model misspecification and contributions from technical and
measurement error that is idiosyncratic to that gene. A major component
of variance is technical. With Affymetrix data analyzed on the log2 RMA
scale, prior experience with many data sets indicates technical variation in
the range of about 0.1–0.5, with values around 0.2–0.3 being quite typical,
suggesting values of ψg will typically range across 0.01–0.25 or thereabouts.
On each mouse i we then have the p-vector response xi defined by x
′
i =
(x1,i, . . . , xp,i) given by
xi =Bhi + εi,(4.1)
where B is the (p × k)-matrix of regression parameters, or design effects,
whose gth row is β′g. The residual p-vector εi = (ε1,i, . . . , εp,i)
′ is distributed
as εi ∼N(0,Ψ), independently over i, where Ψ is the p× p diagonal matrix
of elements ψg (g = 1 :p). In full matrix form with p×n response matrix X =
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[x1, . . . , xn] and p×n residual matrix E = [ε1, . . . , εn], we have X =BH ′+E
with E ∼N(0,Ψ, In), the matrix normal distribution with left variance Ψ
and right variance the n× n identity.
4.2. Multivariate analysis and sparsity. A key biological perspective is
that, though some or all of the experimental groups may be associated with
significant changes in gene expression for a number of genes, many genes
will be unaffected. Further, the complexity represented by higher-order in-
teractions of design factors is unlikely to be realized for many genes. Hence,
we expect each βg vector to have several or all zero elements (apart from
the first); the “tall and skinny” matrix of regression parameters B will be
sparse. The sparsity pattern is unknown and to be estimated—we aim to
identify which entries are nonzero with high probability, and to account for
the fact that with so many genes we need to guard against false discovery.
Analysis with some form of shrinkage approach is mandated. Shrinkage
using point-mass mixture priors—the workhorse for such problems for some
years now—extends standard regression variable selection methodologies to
these problems of large-scale comparisons. Such approaches have been well-
described and quite widely applied in two sample expression studies [50]
and more complex settings [7, 15, 28, 29]. We use practical extensions of the
standard point-mass, mixture priors from variable selection in regression
[10, 17, 43], following developments in studies of sparse multivariate factor
models in [53] that have also been extended to a comprehensive class of latent
factor regression models [9, 35]. These prior studies have explored sparsity
modeling of expression data in biological pathway studies in cancer; the work
here parallels that in the context of atherosclerosis.
4.3. Models of sparsity of design effects. The sparsity model is a stan-
dard variable selection construct that utilizes indicators zg,j = 0/1 such that
zg,j = 1 if any only if βg,j 6= 0, coupled with priors βg,j ∼N(·|0, τj) describing
the distribution of any nonzero effects within design factor j, that is, within
column j of B. This applies to j = 2 :k with nondegenerate models for the
effect-inclusion indicators zg,j , while the intercepts βg,1 are treated simply
via βg,1 ∼N(b, τ1) for some specified prior mean b. The generalization of the
standard sparsity models described in [9, 35] is as follows: for each factor
j = 2 :k, the indicators across variables g are exchangeable, with Bernoulli
probabilities pig,j subject to the hierarchical model
pig,j ∼ (1− ρj)δ0(pig,j) + ρjBe(pig,j|ajmj, aj(1−mj)),(4.2)
where Be(·|am,a(1−m)) is a beta distribution with mean m and precision
parameter a > 0, and the probabilities ρj are modeled as ρj ∼ Be(ρj |sr, s(1−
r)), independently, where s > 0 is relatively large and r a small probability.
The basis for this model is that: (a) with the ρj likely to be small, the model
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places a high probability on many zero values among the pig,j , which in this
application is apt as it emphasizes the biological reality that many genes
should have no probability of responding to an intervention; and (b) with
mj set at relatively high values, the nonzero pig,j will tend to be high, so
that corresponding βg,j are likely to be nonzero.
Key inferential questions concern the identification of genes (if any) that
exhibit significant design effects, and then inferences on those likely nonzero
effects. We will address this by evaluating sets of posterior probabilities
pi∗g,j = Pr(zg,j = 1|X) = Pr(βg,j 6= 0|X) and point estimates such as βˆg,j =
E(βg,j |X,zg,j = 1), along with other posterior quantities.
4.4. Sparse regression components for assay artifact correction. In com-
mon with all microarray assays, Affymetrix array data can exhibit varia-
tion that results from a combination of numerous experimental and assay
sources overlaid on the biologically derived variation of interest. The po-
tential sources include batch effects, unpredictable changes and fluctuations
in experimental controls (hybridization temperatures, salinity, etc.), assay
reagents, technician practices, equipment settings and so forth. Such “assay
artifacts” [9, 35] are often benign and impact on only a few genes per sample
and perhaps a few samples. They can, however, also be quite substantial,
impacting across an entire sample data set and contributing systematic bi-
ases to the summary expression measures for multiple genes. The effects can
be particularly marked when samples are collected over a longer period of
time, whether or not they are processed at the same laboratory. Some form
of the gene-sample specific normalization method is needed to address this.
We use information from housekeeping (or “maintenance”) genes to help
with this. Affymetrix microarrays have a number of gene probes designed
to show either no expression at all or to maintain approximately constant
levels of expression across diverse biological conditions. Such genes can serve
as normalization controls, and the above references have demonstrated the
ability of these probesets to provide covariate information capable of captur-
ing some aspects of assay artifact that shows up in genes of interest. Use of
a few of the dominant principle components among the housekeeping genes
has the ability to capture key aspects of nonbiological assay artifact varia-
tion that may selectively impact on gene subsets across samples, and we use
these principal components as candidate “assay artifact correction factors”
in an expanded model for the vector of expression outcomes. Here we used
the first 5 (of n= 90) principal components of the selected set of 41 “AFFX”
housekeeping probesets on the mouse array. Though these controls may de-
scribe significant artifactual contributions to variation in some genes on some
samples, we recognize that many genes will be quite unaffected on some or
all samples; hence, the use of sparsity priors for regression coefficients on
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these control factors is apt, providing an ability to develop a parsimonious
approach to gene-sample specific, model-based artifact correction.
The extension of the basic sparse anova model of equation (4.1) is im-
mediate. We extend the regression vectors hi to include an additional 5
entries—the values of the assay artifact covariates. The gene specific regres-
sion parameter vectors βg are similarly extended with 5 additional potential
regression parameters per gene, subject to the same form of sparsity prior
as used for the anova design effects.
4.5. Complete model specification. To complete the model specification,
we use priors on the remaining model parameters as follows. For each of the
pij , the required hyperparameters discussed in the previous section are spec-
ified as (r, s) = (0.001,20) and (mj , aj) = (0.9,10) for each j = 2 :k. A diffuse
prior is specified for the intercepts βg,1 ∼N(b, τ1) with (b, τ1) = (8,100) (re-
call we have data on the log2 Affymetrix scale for which expression values
range from near zero to 15–16). For j > 1, the τj parameters are variances
defining the levels of change in average expression for any genes that do
associate with factor group j. Thus,
√
τ j is on the log2 expression scale
and realistic prior expectations indicate values outside a range of 0.5–5 are
unlikely. We adopt relatively diffuse conditionally conjugate inverse gamma
priors τ−1j ∼Ga(τ−1j |5/2,1/2) to reflect this. The residual variance terms ψg
have rather diffuse inverse gamma priors ψ−1g ∼Ga(ψ−1g |25/2,0.1/2). With
Affymetrix data on the log2 RMA expression, or similar, scale, experience
with multiple studies of designed experiments suggest standard deviation
values in the range 0.1–0.3 or thereabouts, and this prior is consistent with
and informed by such experiences.
4.6. Computations. Model fitting uses standard Markov chain Monte
Carlo (MCMC) methods in a relatively routine (though high-dimensional)
Gibbs sampling format with some Metropolis–Hastings components. Details
appear in [9, 35] for a more general model framework. Software implement-
ing the analysis is freely available—the BFRM (Bayesian Factor Regression
Model) code implements sparse statistical models for high-dimensional data
analysis based on latent factor models coupled with sparse regression and
anova; the analysis here uses just the latter components. The MCMC was
initialized at values consistent with the prior and data and the simulation
run for 10,000 iterations to achieve nominal burn-in before saving and sum-
marizing samples for a series of 100,000 iterations.
The MCMC analysis generates posterior samples for all model parameters:
B, the indicators zg,j , the values of the posterior effect probabilities pi
∗
g,j , the
τj , the residual, idiosyncratic variances in Ψ and the sparsity base rates ρj .
These samples can be summarized to produce (Monte Carlo approximations
to) posterior means and uncertainty evaluations for all quantities.
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Fig. 1. Boxplots of the posterior probabilities of nonzero effects pi∗j,j for all g = 1 :p genes
within each of the j = 2–16 design groups (j = 1 represents the intercept), together with
those for the four included assay artifact control covariate factors j = 17–20.
5. Analysis of murine atherosclerosis gene-environment study.
5.1. Analysis set-up. The analysis was run on RMA expression indices
of p= 5328 Affymetrix probesets (genes) on the mice arrays. The restriction
to these genes was based on the interest in mapping to human samples
[discussed further below (Section 7)] and this involved an initial reduction
to 7381 gene probesets on the mice array that have homologues on the
Affymetrix HU95av2 human array used to assay RNA from human aorta
samples in our prior study [51]. Of these 7381, we then removed probesets
showing little or no variation above noise levels (absolute change across
samples less than 0.25, and median across samples lower than 5.0, applied
to both mouse and human samples separately) to deliver the consensus 5328
genes for study. Some investigations of aspects of the resulting posterior
distribution over all model parameters are now detailed.
5.2. Significant gene-design factor associations. Examination of the prob-
abilities pi∗g,j of nonzero effects (Figure 1) indicates interest with respect to
the ApoE-/-interactions ApoE.Age (design group j = 6), ApoE.Diet (group
j = 8) and ApoE.Age.Diet (group j = 13), as expected; these are the key
risk factor groups. The extent of the evidence for significant effects for any
individual gene (Figure 1 and Table 2) indicate also that, beyond genes in
these risk categories, there are small numbers of genes showing evidence of
expression changes as a function of Age, Sex, Diet and (very modestly) their
second order interactions. These are also expected.
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In addition, just one of the assay artifact control factors appears to con-
tribute significantly to expression patterns of a substantial number of genes,
while the others are of negligible importance. Of the subsets of genes linked
to the environmental factors and their relevance as risk measures within the
mouse disease model, Figure 2 shows how the numbers break down into genes
that are unique to the selected subsets on each interaction, and those that
overlap either two or all three of the interaction subsets, based on a purely
nominal threshold of pi∗g,j > 0.95. Genes in the central three-way overlapping
group should be of clear biological interest for further study in relation to
known or hypothesized mechanisms of disease development and maturation,
while the sets in the two-interaction overlap groups bear additional study.
These sets of genes are fully described in a table in the web-based supple-
mentary material, and aspects of the biological relevance and interpretation
appears in Sections 5.3 and 6 below.
Exploring ranked lists of genes by each factor group provides insights
into the strength and nature of associations with risk factors, and poten-
tially on the biological underpinnings based on genes so identified. Selection
of genes might include studying posterior probabilities, odds ratios or meth-
ods of false discovery control including posterior expected false discovery
computations [15, 16], in tandem with estimated effects parameters βg,j .
We explore genes ranked by posterior probabilities and then by absolute
values of the approximate posterior means of the βg,j effects. The latter
are reported along with the gene identifiers for the intersecting risk groups
noted above. We do not regard this as anything more than an exploratory
Table 2
Numbers of genes with high posterior association probabilities pi∗g,j for those
effects/parameters for which significant associations are identified in the mice models
data analysis
#{g :pi∗g,j > q}
j Parameter q = 0.90 q = 0.95 q = 0.99
2 ApoE-/- 49 35 27
3 12wk 68 57 45
4 Male 6 6 5
5 Western diet 27 19 8
6 ApoE-/-, 12wk 49 40 19
8 ApoE-/-, Western diet 173 100 34
9 12wk, Male 5 2 2
10 12wk, Western diet 8 4 0
11 Male, Western diet 45 29 6
13 ApoE-/-, 12wk, Western diet 328 228 111
18 Artifact control factor 2 689 417 119
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Fig. 2. Numbers of significant genes (pi∗g,j > 0.95) in each of three key gene-environment
interaction design groups, with indication of the numbers of genes in the intersections of
the identified gene groups.
analysis to prioritize subsets of genes for exploration in the biological liter-
ature or for further study. In particular, we do not regard this exploratory
analysis summary as at all linked to a formal decision process, and view
much of the statistical literature on false discovery as overly stylized and
of little relevance to summarizing a data analysis. Ultimately, the posterior
probabilities of the nonzero factor effects (already appropriately “corrected”
for the inherent multiplicities through the use of the hierarchical shrinkage
model) are the key summaries, and biological evaluation the only proper
basis for including/excluding any genes with respect to defined statistical
significance. That said, for summary in examples such as this, presenta-
tion of analysis summaries in terms of patterns of gene expression and gene
names requires a choice; we threshold at pig,j > 0.95 here for the sake of
argument. Genes showing high associations with more relaxed thresholding
may of course prove to be of interest and this form of post-analysis study
may be repeated.
5.3. Gene-by-factor evaluation. The expression intensities of four genes
are graphed in Figure 3. The data are labeled x, and the frames show fit-
ted components of the model for those design factors for which pi∗g,j > 0.95
together with the fitted residuals. This displays the breakdown of expres-
sion into significant contributions from these sources for these genes, each
of which is known to be related to the atherosclerosis. We use these genes
as examples of model-based decomposition and attribution of the patterns
of variation in expression to design factors and their interactions.
Osteopontin (named minpontin in the mouse genome), a major player in
cardiovascular diseases and in atherosclerosis in particular [18], is involved
in mediating processes of cellular adhesion and migration, activities that
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are central to vascular remodeling in plaque formation and development,
among other functions. Here the expression levels of osteopontin are signifi-
cantly increased with both age and diet risk factors separately among disease
prone mice, as well as substantially more so for the j = 13 interaction group
of very advanced disease, so it plays a role as a generic disease marker.
VCAM1 (vascular adhesion molecule 1) is a central marker of the disease,
being known to play a pivotal role in the initiation of atherosclerosis and
to be highly expressed in arterial endothelial cells in regions predisposed to
atherosclerosis and atherosclerotic plaques [13]. VCAM1 is significantly up
among older ApoE-/- mice and more so among those on the Western diet.
Thrombospondin is well known to be associated with a variety of cellular
processes relevant to atherosclerosis, including vascular smooth muscle cell
Fig. 3. Expression decompositions of selected genes in the mice data analysis. In each
frame, the plots over time are expression data x, fitted model components from design
and regression factors showing significant (pi∗g,j > 0.95) contributions for the specific gene,
and residuals. Expression is effectively the direct sum of the components and residuals
plotted. In each frame the data and components are plotted on the same vertical scales for
comparison. Labels j = 6,8,13 represent the fitted design effects for the three groups, c2
the fitted effects of the second assay artifact correction factor, and e the residuals.
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migration, and increased expression levels are markers of advanced disease
states in atherosclerosis as in other diseases [37]. The analysis here reflects
this, identifying practically large increases in expression only in the advanced
disease group—older, Western diet fed ApoE-/- mice—but not due to diet
and age alone. TNFR (tumour necrosis nuclear factor receptor) plays a role
in the induction of expression of adhesion molecules including VCAM1 and
promoting inflammation within vascular endothelial cells [57], and serves
as a marker of advanced disease states. We see this reflected in increased
expression levels among older ApoE-/- mice on the Western diet, but not
across the other design groups. TNFR is also an example of a gene whose ex-
pression patterns show significant association with one of the experimental
artifact covariates, and this shows how the correction model aids in isolating
biologically interpretable components of expression fluctuations from data
corrupted with experimental and artifactual noise.
5.4. Metagene signatures of risk groups. Several additional figures dis-
play summaries of the expression data of these key gene subsets in terms
of summary overall measures defining signatures of the subsets. We do this
via the factor metagene of any gene set—simply the first principal com-
Fig. 4. Expression image of genes in the mice ApoE.Age signature (design group j = 6).
The older, ApoE-/- mice are those numbered 65–90 inclusive.
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ponent (singular factor) of the subset of genes. This follows the original
introduction of the term “metagene” [54, 55] and its use in defining a single
Fig. 5. Metagene signatures of selected design groups. In each, the graph displays the first
principal component of the set of genes showing high probability (pi∗g,j > 0.95) of change in
expression with respect to the design group. The color coding simply identifies mice samples
in the corresponding group. For example, in the upper-left frame red indicates ApoE-/-
while blue indicates wild type; in the centre-right frame, red indicates older ApoE-/- mice;
in the lower-left frame, red indicates older mice on the Western diet, and so forth (see
also the metagene signature image/heat-map in Figure 1 of the supplementary material).
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numerical “signature” of a set of genes in biological experimental contexts
[4, 5, 6, 21, 23], as well as in a number of observational disease studies
[20, 22, 41, 45, 51] using gene expression technologies. Given a set of indices
Q ∈ 1 :p with |Q| = q, write XQ for the q × n matrix of expression values
across the n samples. The SVD is XQ =ADF , where A is the q × r eigen-
vector matrix with orthonormal columns, D is the r× r diagonal matrix of
singular values, F is the r × n orthogonal matrix of singular factors, and
r =min(q,n). If aQ,1 is the first column of AD
−1, then f ′1 = a
′
Q,1XQ is the
first row of F and gives the n values of the first singular factor across the
samples. In cases of reduced rank, some elements of D will be zero and
A,D and F are reduced by deleting the corresponding columns, diagonal
elements and rows, respectively. The vector aQ,1 represents a signature of
the gene subset Q, and the factor f1 the corresponding metagene evaluated
over samples. In cases when Q represents a set of coherently related genes
with a dominant overall pattern, such as genes whose expression levels tend
to be high in one risk category, aQ,1 is a characterizing signature of that
category.
In practice, we apply this construction not to the raw data XQ but to that
“corrected” by the fitted model; for each gene, we subtract the contributions
from the overall mean and the regression on the artifact control factors (each
term of the form βˆg,jpi
∗
g,j , where βˆg,j is the posterior mean of βg,j) to produce
centred and artifact-corrected versions of gene expression values.
As one example, Figure 4 shows expression intensities of the q = 40 genes
characterizing one of the gene-environment interaction groups, the older
ApoE-/- mice (j = 6). This is an overall, visual “signature” of the group, and
the extent of changes in expression among older knockout mice is apparent.
The metagene factor generated is plotted across samples in (the center-right
frame of) Figure 5; it is clear that this single factor provides a clear and
distinctive signature of the risk group. Additional metagenes for other design
groups appear in the figure, and highlight the characterization of several of
the genetic and environmental factors in terms of single expression signatures
of relevant genes.
6. Genes identified in key risk groups. The above discussion highlights
three key design groups related to gene-environment interactions; genes char-
acterizing these groups are of interest in connection with identifying prog-
nostic summaries of gene expression linked to advancing disease state. The
discussion named some such genes that have known functions in the devel-
opment and progression of atherosclerosis, and similar features arise with
multiple other known genes, especially subsets related to the immunological
and inflammatory responses characteristic of atherogenesis. We now look
at the potential to aid further biological evaluation by perhaps identifying
novel candidates linked to the disease process.
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The association of age and diet with the development and progression of
atherosclerosis is well accepted. One of the results here is the proposal of
genes that are associated not just with the presence or absence of atheroscle-
rosis but also at the interaction with age, diet or both. The interaction be-
tween atherosclerosis and age is quite clear. The prevalence of atherosclerosis
in subjects over the age of 70 exceeds 50%; in men alone, the prevalence ap-
proaches 70% by age 70. This is not surprising as mechanisms of aging are
also mechanisms involved in atherosclerosis. Two major aging mechanisms
are the damage caused by oxidative stress and by the deposition of advanced
glycoslyation end products (AGE proteins), both of which lead to extensive
apoptosis. Among the list of genes in the ApoE.Age risk group are CD53 and
galectin 3, neither of which has, to our knowledge, been directly implicated
in the disease process to date.
CD53 is a glycoprotein of the tetraspanin superfamily associated with the
recycling enzyme gamma-glutamyl transpeptidase [3]. As such, CD53 plays
a role in redox buffering of cells to provide protection from oxidative stress
[33, 39]. CD53 expression is elevated in situations of increased oxidative
stress such as in rheumatoid arthiritis, radiation damage and also aging,
and its expression appears to counter the acceleration of programmed cell
death by oxidative damage. Galectin 3 is a member of the beta-galactoside-
binding gene family. In cancer, galectin 3 contributes to tumor cell adhesion,
proliferation, differentiation, angiogenesis and metastasis [38]. Its primary
biological effect appears to be to decrease cell death by making cells less
sensitive to pro-apoptotic pathways. In arterial tissues, galectin 3 appears to
play a protective role against the damage caused by advanced glycosylation
end-products (AGE) [42]. In animal models that carry a galectin 3 knock-
out, there is a substantial increase in damage from AGE deposition relative
to control animals [24, 25]. The activity of AGE-proteins is a mechanism for
diabetes associated damage and also age-related vascular damage [56].
The interaction between atherosclerosis and diet, especially cholesterol, is
well established; the mechanism is through deposition of low density lipopro-
tein cholesterols into the vascular tissues with development of inflammation
and apoptosis. Two genes in the ApoE.Diet risk group are Caspase 9 and
insulin like growth factor receptor 1 (ILGFR1).
Caspase 9 is part of a group of proteins that play a central role in pro-
grammed cell death or apoptosis. Some of the most important mechanisms
in the development of atherosclerosis revolve around the pathways triggered
by elevated serum cholesterol [32, 40]. One specific mechanism is that high
levels of cholesterol induce apoptosis in endothelial and smooth muscle cells
in the vasculature. Caspase 9 plays a direct role in modulating apoptosis
[48, 52]. ILGFR1 mediates the activity of the insulin like growth factor, and
this has a number of mitogenic effects in the cardiovascular system, some
of which are linked to hypercholesterolemic conditions [1, 19]. High levels
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of serum cholesterol, particularly low density lipoproteins (LDL), activate
the different components of the arterial wall. The vascular smooth muscle
cells, in response to high LDL levels, undergo proliferation, differentiation,
as well as apoptosis as a part of atherosclerosis development [1, 2, 47]. One of
the mechanisms by which high LDL levels are believed to activate vascular
smooth muscles is through the modulation of insulin like growth factor re-
ceptor expression. The combination of age and cholesterol lends individuals
to an even higher risk for atherosclerosis. Two genes in the ApoE.Age.Diet
risk group, Interleukin 1 receptor antagonist (IL1RN) and Clusterin, par-
ticipate in all aspects of damage for both diet and aging—inflammation,
apoptosis and oxidative stress. IL1RN is a naturally occurring antagonist for
the inflammatory cytokine interleukin 1 (IL1). Animals deficient for IL1RN
develop significantly higher levels of serum cholesterol and atherosclerosis
relative to animals with normal ILRN levels [14, 30]. These animals also de-
velop uncontrolled inflammation, particularly within the vascular tree. These
animals are also particularly susceptible to the apoptotic effects of elevated
cholesterol. In humans, elderly individuals have been shown to have signifi-
cantly higher levels of circulating IL1RN relative to younger individuals [46].
The overproduction of IL1RN is believed to counter the proinflammatory
and proapoptotic effects of age. Clusterin is a glycoprotein that is widely
distributed throughout the body [8]. It has been shown to reduce oxidative
stress in a number of different biological contexts, such as cigarette smoke
exposure and animal models of autoimmune disease, and also to play a role
in modulating inflammation [8, 49].
These are a few examples of a larger set of genes showing significant asso-
ciation with the key risk groups and for which there are clear and defensible
biological mechanisms by which they may be implicated in the atheroscle-
rotic disease process, though to our knowledge no direct evidence has been
earlier identified in the literature.
7. From mouse to human: Perspective. From our prior studies of ex-
pression from RNA in the inner walls of human aortic tissue [51], we have
expression profiles on n= 122 individuals. This prior data set also includes
the (albeit rather crude) measures of the extent of disease evident within
the aortas in terms of percent area affected with raised lesions and also the
SudanIV staining measure, as discussed in Section 2. This data set provides
the opportunity for an exploratory analysis to evaluate: (a) the extent to
which genes identified in key risk groups in the mice models study show
evidence of variation in expression in the human samples; (b) the nature of
patterns of variation and covariation of the disease related mice genes when
explored in the human data; and (c) the extent to which disease risk signa-
tures developed in the mice study relate—if at all—to disease measures in
the human samples.
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The first step is to link gene probesets across the two microarray plat-
forms, matching genes on the mouse U74av2 array to orthologous sequences
on the human U95av2 array. With the current Affymetrix mice and human
arrays, this naturally involves cases in which no multiple human gene probe
sets are linked to a single mouse probe set, other cases in which multiple
human probes sets are matched to a single mouse gene, and cases in which
one human gene/probe set is matched to multiple mouse probe sets. In
the first case, when no human probe set exists on the Affymetrix U95av2
chip, we simply ignore that mouse gene. In the second case, multiple human
probe sets identified as orthologous to the gene represented are evaluated
for sequence similarity and a single human gene/probe set selected based
on sequence match, the others being ignored. In the third case, we focus
only on the unique human genes/probe sets identified. The analysis of the
mice experiments described above was in fact performed following such a
mapping, this preliminary matching playing a role in defining the number of
mice array sequences as mooted earlier. The human U95av2 array has 12588
primary probesets and an additional 67 “AFFX” control probes; the mouse
U74av2 array has 12422 primary probesets and an additional 66 control
probes. When mapped, the consensus groups involve 7381 gene probesets
and 41 common AFFX controls. The former was reduced to 5328 as men-
tioned, and the data on the latter define assay artifact control covariates.
8. Mice model risk signatures evaluated in human samples. Following
the mapping of a set of mouse genes Q to the corresponding human genes,
we can evaluate the signature defined by the metagene aQ,1 of the mice gene
subset (Section 5.4) against the human data. If XQ now represents the hu-
man data matrix on this gene subset (genes as rows, samples as columns),
then the extrapolated signature across human samples is simply a′Q,1XQ.
Following the use of metagene signatures in the mice model analysis, we ap-
ply this construction not to the raw human data XQ but instead to human
data corrected for potential artifacts. The sparse factor model analysis de-
scribed in the following section incorporates assay artifact correction terms
completely parallel to those included in the mouse model analysis, providing
for estimation of the underlying patterns of covariation in the human ex-
pression data in the context of a model able to correct—to some degree—for
experimentally induced noise and artifactual biases.
Figure 6 displays the projected signatures for four selected groups: the
three key gene-environmental risk groups and the older, Western diet-fed,
Wild Type mice for contrast. The mice data appear first in each frame.
Signatures plotted in the first three frames are those of the risk groups as
in Figure 5; in contrast to these, the Age.Diet mice signature in the fourth
frame (lower right) indicates very limited discrimination between the older,
Western diet fed Wild Type mice and the rest. Mice signatures are followed
SPARSE STATISTICS AND GENOMICS 19
Fig. 6. Selected expression signatures of risk-related gene groups evaluated in mice sam-
ples and projected onto human samples (see also Figure 2 of the supplementary material).
by the projections onto human samples. The red human cases are positive
for raised lesions, while blue cases have no visible evidence of lesions.
As discussed earlier, the raised lesion measure is a relatively crude indica-
tor of disease state and progression. Among other questions of its precision
as a disease phenotype, it is clear that some individuals with advanced dis-
ease may show no evidence of lesioning on the surface of the inner walls of
the aorta at all, lesions may be missed in inspection due to selection of tissue
regions to examine, lesioning may be evident very locally within a small area
of the aorta, and gene expression is defined on mRNA extracted from one
isolated section of aortic tissue. Nevertheless, as the only available disease
state measure, it is of interest to note that the projected expression signa-
tures of the three key risk groups (ApoeE.Age, ApoE.Diet, ApoE.Age.Diet)
show evidence of some discrimination; from Figure 6, roughly half of the
“diseased” human cases have high signatures corresponding to these three
diseased states in the mice. Though purely exploratory, this does suggest
that disease-risk related expression markers can be extrapolated with value
from animal to human contexts, and that some degree of variation across
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samples due to advancing disease is evident in the projection, in spite of the
potential shortcomings of the data and the cross-species extrapolation.
9. Sparse factor analysis of human gene expression data.
9.1. Goals and model framework. Among the questions arising in map-
ping experimentally derived signatures to observational data are those of
just how unrealistic the underlying, experimentally induced changes in gene
expression are relative to patterns of normal biological variation. This is a
question faced in the current study as in other such studies of cancer related
genes [4, 21], for example. Some of the genes perturbed in the experimen-
tal context may show little or limited variation at all in normal biological
samples, and the extent of expression change in key experimental signature
genes is likely to be dramatic compared to normal fluctuations. Further, the
complexity of interactions of relevant pathways can be expected to induce
more complex patterns of association that are evident in the human obser-
vational samples. To explore these questions, we use latent factor models
to capture aspects of expression covariation in the human data set, focused
on sets of genes that include those identified in the experimental risk signa-
tures. This is a direct application of a general latent factor regression model
approach that simply extends the sparse multivariate regression model to
incorporate regressors that are uncertain [9]—latent factors reflecting the
complexity of purely observational associations among genes evidenced in
the human data set. We can then ask how estimated factors relate to the
signatures projected from the mouse experiments. This provides some op-
portunity to examine concordance of projected signatures with key aspects
of “normal” patterns underlying gene expression.
We use the same basic notation, now applied to the human gene expression
data rather than the mice. On each human sample i= 1 :122, the p-vector
of gene expression responses xi is modeled as
xi =Aλi +Bhi + εi.(9.1)
Now B is the design matrix that includes a column of 1’s followed by the
values of the first five assay artifact factors computed on the human ar-
ray housekeeping genes, so that βg represents the gene-specific intercept
and artifact regression parameters. This is precisely as in the mouse model
analysis, though without the design components, of course. The additional
factor model structure involves the k-vector of latent factors λi and the
corresponding sparse factor loadings matrix A. The structure and set-up
is precisely as described in [9] and also [35]. At a mathematical level the
model is just an extension of the multivariate sparse regression in which
the λi vectors are themselves now uncertain. In [9] we describe the use of
nonparametric model components for the distribution of the latent factors,
SPARSE STATISTICS AND GENOMICS 21
a model that permits flexibility in evaluation of potentially complicated pat-
terns of interdependencies among genes in xi while adapting to what may be
a quite non-Gaussian structure. The model involves Dirichlet process priors
for the latent factor distribution, and also has the feature of cutting back to
Gaussianity if the data suggests that is reasonable.
The analysis parallels that of the sparse anova regression model in that
it delivers posterior probabilities pi∗g,j for all genes g in the model and all
latent factors j = 1 :k, together with the sparse regression components in-
volving the assay artifact controls. The analysis was initiated with a set of
63 initial genes from the three key mice risk sets. Aiming to select a small
initial core set of genes relevant to atherosclerosis risk as defined by the mice
data analysis, we selected subsets at the genes for which pi∗g,j > 0.99 in the
mice study for these three risk groups j = 6,8,13, restricting to at most 25
genes from each of the three sets. This yielded a total of 63 unique genes to
initiate the evolutionary factor model search analysis [9]. Briefly, this analy-
sis iteratively refits the latent factor regression model, at each iterate based
on a “current” set of genes beginning with these 63. Within each step the
model is revised to expand the number k of latent factors fitted and that
each show association with more than a few genes. This is followed by an
approximate computation of the predictive probability of gene-factor load-
ings for all genes not currently included; that is, for all genes g not currently
in the model, probabilities analogous to pi∗g,j for all factors j in the cur-
rent model. This provides a ranking of nonincluded genes according to how
strongly they appear to associate with each of the latent factors. The model
can then be extended by including some such genes, assuming subsets show
relatively high gene-factor associations. Once the gene set is extended, the
factor model is refitted, including possible increase in the number of latent
factors. Here we ran this analysis to allow genes to be included only if their
maximum predicted probability of inclusion exceeded 0.75, and a factor to
be added to increase the dimension of λi only when at least five genes cur-
rently in the model showed pi∗g,j > 0.75. We also restricted the evolutionary
expansion of the model to terminate with at most 150 genes in total and the
terminal model has k = 10 latent factors on 150 genes. At each stage, the
MCMC used burn-in of 2000 iterates followed by a Monte Carlo sample of
size 8000.
The key concept underlying the evolutionary analysis is to enrich the
initial set of “risk related genes” with genes that share latent factor-based
associations within the human observational data set; the final model is
then an enriched representation of “normal” variation among putatively
risk related genes. Full details of the modeling and computational strategy
appear in the above reference, and the MCMC analysis of this class of latent
factor regression is implemented and exemplified in the BFRM software.
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Fig. 7. Expression decompositions across human aorta samples of the four risk-related
genes illustrated in Figure 3. In each frame, the plots over time are expression data x, fitted
model components from the subset of latent factors and assay artifact controls showing
significant (pi∗g,j > 0.95) contributions (if any) for that gene, and residuals. Expression is
effectively the direct sum of the components and residuals plotted, and within each frame
the data and components are plotted on the same vertical scales for comparison. Labels
f1, f2, . . . represent fitted latent factor effects for factors 1, 2, and so forth, c3 the fitted
effects of the third assay artifact correction factor, and e represents residuals.
9.2. Aspects of risk-related factor structure in human data. Figure 7 dis-
plays data for the four example “risk-related” genes identified in the mice
data analysis (Figure 3). As in the mice analysis figure, these represent de-
compositions of expression across samples, with each gene decomposed into
significant contributions from the model factors or regressors. The samples
are ordered as earlier so that the last 33 samples are those showing evidence
of more advanced disease in terms of raised lesions.
It appears that each of these genes does indeed tend to show higher levels
of expression in later samples, though with much variation and no clear or
really obvious step or ramp-up of levels among the “diseased” cases. Two of
these genes (Thrombospondin and TNFR) are, among others, significantly
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associated with latent factor 3; the posterior mean of factor 3 across sam-
ples shows a clearer pattern of higher values among later samples, though
again with volatility. Thus, factor 3 seems to be an inherent pattern in the
observational data set that relates, to a degree, to the increased disease risk
measured by lesions, and reflects a key contributing pattern to the overall
expression of these known risk marker genes. Among the 150 genes in the
analysis, 37 show significant association (pi∗g,j > 0.95) with factor 3, includ-
ing a number from the initial risk set but also additional genes that were
identified as part of the evolutionary analysis. This points to the potential
for this form of analysis to take a step-ahead in identifying additional gene
candidates for further study in connection with disease risk processes, and
some of these genes not previously identified as risk related are worth in-
vestigating further. Factor 4 also appears to relate to risk, as evidenced in
the plot for VCAM1. Factor 4 appears significantly loaded on a smaller,
biologically very cohesive set of genes that include representative probesets
for VCAM1 and others, and as apparent in the decomposition of VCAM1 in
the figure, shows a (weak) relationship with the more diseased individuals.
Thus, the factor analysis has identified two distinct patterns of common as-
sociation in the normal variation of expression profiles, each related to risk
and potentially reflecting underlying substructure in disease related path-
way activity. Finally, Figure 8 shows the concordance between the estimated
factor 3 and the projection from the mice data analysis of the metagene sig-
nature corresponding to the j = 6 (ApoE-/-, Age) risk factor group. The
remarkable concordance indicates that the overall pattern of natural varia-
tion in expression that factor 3 captures and reflects is inherently consistent
Fig. 8. Left frame: The posterior mean of latent factor f3 in the human aorta analy-
sis, plotted across samples. The red cases are those for which there is evidence of raised
lesioning within the inner wall of the aorta, that is, the more advanced disease cases, with
lesion index increasing with sample index number (see Figure 2 of the supplementary ma-
terial). Right frame: The same estimated factor 3 scatter-plotted against the projected risk
signature from the j = 6 (ApoE-/-, Age) risk factor group from the mice data analysis.
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with that observed in the controlled and artificial experimental context. This
gives further credence to the view that the gene subsets underlying these fac-
tors and signatures are indeed likely to be both predictive of disease states
in human contexts and suggestive of directions to investigate for improved
biological understanding.
10. Concluding comments. The analysis of the experimental mice data
generates robust patterns of expression that are influenced by the interac-
tions of the effects of key, known risk factors; these patterns can be charac-
terized by metagene signatures of the effects and interactions of the gene-
environmental factors. When mapped to human expression data, with all
of the issues of data comparability, cross-species and technological issues
that raises, these patterns relate to the key current measure of extent of
atherosclerotic disease burden in observational human aorta samples. The
groups of genes identified clearly link to much of what is known about the
disease process and its development with age and as response to diet, while
also isolating additional genes that are potentially important modifiers of
atherosclerotic risk in the setting of specific risk factors. This application is
an example of an approach to dissecting gene-environment interactions on a
genomic scale in the context of a critical, complex human disease, and one
that is being used in other areas including cancer studies.
The study also serves to illustrate the utility of sparsity modeling in mul-
tivariate, high-dimensional anova, regression and latent factor models. Al-
though the statistical framework and methodology used for these applica-
tions are generic and applicable in other fields, a major motivation in their
development has been biological pathway and translational studies using
gene expression data, and other forms of high-throughput molecular data
in both designed experimental contexts and observational studies. As high-
throughput arrays and related technologies become desk-top commodities,
we can expect to see a major increase in the scale and complexity of designed
experiments on multiple factors generating high-dimensional responses. Fac-
torial designs will become de rigeur within molecular and genome biology
in the way they were in the early 20th century in agricultural research, and
the need for relevant statistical analysis tools will be evermore central. Spar-
sity and shrinkage modeling are fundamental and, though the specific forms
of models used here are just examples, the framework is clearly extensible
to other similar contexts. Coupled with that, sparse latent factor models
for observational data sets provide complementary approaches to deconvo-
lution and attribution of complex, interacting patterns of association in data
that may reflect inherent, underlying biological processes and pathway sub-
structure. As in cancer applications [9, 35], these methods can play roles in
studies to elucidate gene-environment interactions in critical and challenging
biomedical contexts such as atherosclerosis.
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material at http://ftp.stat.duke.edu/WorkingPapers/07-05.html and
also linked to the paper at the journal web site.
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